Predictors of quality of life in inpatients with schizophrenia

Psychiatry Research

Volumn 197, Issue 3, 2012, Pages 199-205

  Fujimaki, Koichiro ^a   Morinobu, Shigeru ^b   Yamashita, Hidehisa ^b   Takahashi, Terumichi ^c   Yamawaki, Shigeto ^b  

^a PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Mihara Hospital   (Japan)

Author keywords

Inpatients; Negative symptoms; Quality of life; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PEROSPIRONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TIMIPERONE; ZOTEPINE;

ADULT; AGE; ARTICLE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DISEASE DURATION; EDUCATIONAL STATUS; EXTRAPYRAMIDAL SYNDROME; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INVOLUNTARY MOVEMENT; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NERVE CONDUCTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DYSKINESIA, DRUG-INDUCED; EDUCATIONAL STATUS; FEMALE; HUMANS; INPATIENTS; JAPAN; LENGTH OF STAY; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS AS TOPIC;

EID: 84865077433     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.10.023     Document Type: Article

References (63)

1. Aki H., Tomotake M., Kaneda Y., Iga J., Kinouchi S., Shibuya-Tayoshi S., Tayoshi S.Y., Motoki I., Moriguchi K., Sumitani S., Yamauchi K., Taniguchi T., Ishimoto Y., Ueno S., Ohmori T. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Research 2008, 158:19-25.
2. Allison D.B., Mackell J.A., McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 2003, 54:565-567.
3. Awad A.G., Voruganti L.N., Heslegrave R.J. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Quality of Life Research 1997, 6:21-26.
4. Awad A.G., Voruganti L.N., Heslegrave R.J. Measuring quality of life in patients with schizophrenia. PharmacoEconomics 1997, 11:32-47.
5. Bellack A.S., Sayers M., Mueser K.T., Bennett M. Evaluation of social problem solving in schizophrenia. Journal of Abnormal Psychology 1994, 103:371-378.
6. Brazo P., Delamillieure P., Morello R., Halbecq I., Marie R.M., Dollfus S. Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. Psychiatry Research 2005, 133:45-55.
7. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry 1991, 48:239-246.
8. Browne S., Roe M., Lane A., Gervin M., Morris M., Kinsella A., Larkin C., Callaghan E.O. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica 1996, 94:118-124.
9. Browne S., Garavan J., Gervin M., Roe M., Larkin C., O'Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. The Journal of Nervous and Mental Disease 1998, 186:74-78.
10. Caron J., Mercier C., Diaz P., Martin A. Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Research 2005, 137:203-213.
11. Crossley N.A., Constante M., McGuire P., Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. The British Journal of Psychiatry 2010, 196:434-439.
12. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003, 60:553-564.
13. Dickerson F., Boronow J.J., Ringel N., Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophrenia Research 1996, 21:75-83.
14. Dickerson F.B., Ringel N.B., Parente F. Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatrica Scandinavica 1998, 98:124-127.
15. Dickinson D., Coursey R.D. Independence and overlap among neurocognitive correlates of community functioning in schizophrenia. Schizophrenia Research 2002, 56:161-170.
16. Fitzgerald P.B., Williams C.L., Corteling N., Filia S.L., Brewer K., Adams A., de Castella A.R., Rolfe T., Davey P., Kulkarni J. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica 2001, 103:387-392.
17. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. The American Journal of Psychiatry 1996, 153:321-330.
18. Green M.F. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. The American Journal of Psychiatry 2007, 164:992-994.
19. Guy W. Abnormal Involuntary Movement Scale (AIMS); ECDEU Assessment Manual for Psychopharmacology 1976, 534-537. U.S. Dept. of Health, Education and Welfare.
20. Han T.S., Tijhuis M.A., Lean M.E., Seidell J.C. Quality of life in relation to overweight and body fat distribution. American Journal of Public Health 1998, 88:1814-1820.
21. Hasegawa K. The clinical issues of age-related dementia. The Tohoku Journal of Experimental Medicine 1990, 161(Suppl):29-38.
22. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984, 10:388-398.
23. Heslegrave R.J., Awad A.G., Voruganti L.N. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. Journal of Psychiatry & Neuroscience 1997, 22:235-243.
24. Ho B.C., Nopoulos P., Flaum M., Arndt S., Andreasen N.C. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. The American Journal of Psychiatry 1998, 155:1196-1201.
25. Hofer A., Rettenbacher M.A., Widschwendter C.G., Kemmler G., Hummer M., Fleischhacker W.W. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience 2006, 256:246-255.
26. Huppert J.D., Weiss K.A., Lim R., Pratt S., Smith T.E. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophrenia Research 2001, 51:171-180.
27. Inada T. Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage 1996, Seiwa Shoten Publishers, Tokyo.
28. Inagaki A., Inada T. Dose equivalence of psychotropic drugs. Part 18: dose equivalence of psychotropic drugs: 2006-version. Japanese Journal of Clinical Psychopharmacology 2006, 9:1443-1447. (in Japanese).
29. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006, 63:1079-1087.
30. Kaneda Y., Imakura A., Fujii A., Ohmori T. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Research 2002, 113:107-113.
31. Karow A., Moritz S., Lambert M., Schoder S., Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005, 38:320-326.
32. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 2004, 68:283-297.
33. Kolakowska T. Brief Psychiatric Rating Scale: Glossary and Rating Instructions 1976, Oxford University Press, Oxford.
34. Kurtz M.M., Moberg P.J., Ragland J.D., Gur R.C., Gur R.E. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophrenia Bulletin 2005, 31:167-174.
35. Lachar D., Bailley S.E., Rhoades H.M., Espadas A., Aponte M., Cowan K.A., Gummattira P., Kopecky C.R., Wassef A. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychological Assessment 2001, 13:384-395.
36. Laurent A., Biloa-Tang M., Bougerol T., Duly D., Anchisi A.M., Bosson J.L., Pellat J., d'Amato T., Dalery J. Executive/attentional performance and measures of schizotypy in patients with schizophrenia and in their nonpsychotic first-degree relatives. Schizophrenia Research 2000, 46:269-283.
37. Matsushita T., Matsushima E., Kinomura M., Miyamoto Y., Shinkai N. Evaluation of quality of life for patients with schizophrenia in a chronic ward. Seishin Igaku 2004, 46:621-627. (in Japanese).
38. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999, 25:233-255.
39. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996, 14:27S-33S.
40. Ministry of Health Statistical Surveys Conducted by Ministry of Health, Labour and Welfare in Japan Accessed February 12, 2011, at. http://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo/suiihyo18.html#03.
41. Ministry of Health Statistical Surveys Conducted by Ministry of Health, Labour and Welfare in Japan 2008, Accessed February 12, 2011, at http://www.npo-jam.org/library/materials/m_mhlw03.html.
42. Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 2006, 51:480-491.
43. Nogi K. The challenge in the promotion project for patient's discharge from hospital for the patient with hospitalization for 40 years. The Japanese Psychiatric Nursing Society 2008, 48:46-50. (in Japanese).
44. Norman R.M., Malla A.K., McLean T., Voruganti L.P., Cortese L., McIntosh E., Cheng S., Rickwood A. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatrica Scandinavica 2000, 102:303-309.
45. Okada K., Sudo K., Hirakawa S., Inoue S., Kitazoe N. Analysis of psychopathology in so-called admissions due to social factors. Japanese Journal of Clinical Psychiatry 1996, 25:1059-1066. (in Japanese).
46. Oliver J.P.J., Huxley P.J., Bridges K., Mohamad H. Quality of Life and Mental Health Services 1996, Routledge, London.
47. Oshima I., Yoshizumi A., Inazawa K., Inomata Y., Okagami K. The intention of the community living and the idea of the life style after the discharge expressed by long stay patients: an analysis of a nationwide self-rating survey for long stay schizophrenics in about 40,000 psychiatric beds in Japan. Japanese Journal of Hospital and Community Psychiatry 1996, 38:558-567. (in Japanese).
48. Oshima I., Ito J., Taira N. Need for an integrated program of case management and psychoeducation in long stay psychiatric patients in Japan. Comprehensive Treatment of Schizophrenia: Linking Neurobehavioral Findings to Psychosocial Approaches 2002, 196-203. Springer. H. Kashima, I.R.H. Falloon, M. Mizuno, M. Asai (Eds.).
49. Oshima I., Mino Y., Inomata Y. Effects of environmental deprivation on negative symptoms of schizophrenia: a nationwide survey in Japan's psychiatric hospitals. Psychiatry Research 2005, 136:163-171.
50. Pendleton M.G., Heaton R.K., Lehman R.A., Hulihan D. Diagnostic utility of the Thurstone Word Fluency Test in neuropsychological evaluations. Journal of Clinical Neuropsychology 1982, 4:307-317.
51. Reine G., Lancon C., Di Tucci S., Sapin C., Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatrica Scandinavica 2003, 108:297-303.
52. Ritsner M., Modai I., Endicott J., Rivkin O., Nechamkin Y., Barak P., Goldin V., Ponizovsky A. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. The Journal of Clinical Psychiatry 2000, 61:880-889. quiz 890.
53. Spaulding W.D., Storms L., Goodrich V., Sullivan M. Applications of experimental psychopathology in psychiatric rehabilitation. Schizophrenia Bulletin 1986, 12:560-577.
54. Stip E., Remington G.J., Dursun S.M., Reiss J.P., Rotstein E., MacEwan G.W., Chokka P.R., Jones B., Dickson R.A. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. Journal of Clinical Psychopharmacology 2003, 23:400-404.
55. Strejilevich S.A., Palatnik A., Avila R., Bustin J., Cassone J., Figueroa S., Gimenez M., de Erausquin G.A. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Research 2005, 133:277-280.
56. Sumiyoshi C., Sumiyoshi T., Nohara S., Yamashita I., Matsui M., Kurachi M., Niwa S. Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. Schizophrenia Research 2005, 74:91-100.
57. Taniguchi T., Sumitani S., Aono M., Iga J., Kinouchi S., Aki H., Matsushita M., Taniguchi K., Tsuno M., Yamanishi K., Tomotake M., Kaneda Y., Ohmori T. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. Human Psychopharmacology 2006, 21:439-445.
58. Tomotake M., Kaneda Y., Iga J., Kinouchi S., Tayoshi S., Motoki I., Sumitani S., Yamauchi K., Taniguchi T., Ishimoto Y., Ueno S., Ohmori T. Subjective and objective measures of quality of life have different predictors for people with schizophrenia. Psychological Reports 2006, 99:477-487.
59. Velligan D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Eckert S.L., Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research 1997, 25:21-31.
60. Voruganti L., Heslegrave R., Awad A.G., Seeman M.V. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychological Medicine 1998, 28:165-172.
61. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 2000, 43:135-145.
62. Wegener S., Redoblado-Hodge M.A., Lucas S., Fitzgerald D., Harris A., Brennan J. Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. The Australian and New Zealand Journal of Psychiatry 2005, 39:487-492.
63. Wilkinson G., Hesdon B., Wild D., Cookson R., Farina C., Sharma V., Fitzpatrick R., Jenkinson C. Self-report quality of life measure for people with schizophrenia: the SQLS. The British Journal of Psychiatry 2000, 177:42-46.